tiprankstipranks
Denali Therapeutics (DE:4DN)
FRANKFURT:4DN
Germany Market

Denali Therapeutics (4DN) Income Statement

Compare
7 Followers

Denali Therapeutics Income Statement

Last quarter (Q3 2024), Denali Therapeutics's total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q3, Denali Therapeutics's net income was $-107.19M. See Denali Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 330.53M$ 108.46M$ 48.66M$ 335.66M$ 26.68M
Gross Profit
$ 313.81M$ 101.43M$ 43.05M$ 123.04M$ -166.70M
Operating Expenses
$ 527.23M$ 449.21M$ 344.41M$ 272.94M$ 239.86M
Depreciation and Amortization
$ 16.73M$ 7.03M$ 5.61M$ 6.17M$ 7.99M
EBITDA
$ -179.97M$ -330.36M$ -287.16M$ 62.72M$ -205.19M
Operating Income
$ -196.70M$ -340.74M$ -295.75M$ 62.72M$ -213.18M
Other Income/Expenses
$ 51.51M$ 14.77M$ 4.59M$ 9.24M$ 15.22M
Pretax Income
$ -145.19M$ -325.97M$ -291.16M$ 71.96M$ -197.97M
Net Income
$ -145.22M$ -325.99M$ -290.58M$ 71.14M$ -197.61M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -1.06$ -2.60$ -2.39$ 0.65$ -2.07
Diluted EPS
$ -1.06$ -2.60$ -2.39$ 0.63$ -2.07
Weighted Average Shares Outstanding
137.37M 125.53M 121.52M 108.97M 95.61M
Weighted Average Shares Outstanding (Diluted)
137.37M 125.53M 121.52M 112.70M 95.61M
Currency in USD

Denali Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis